Date: 2012-12-19
Type of information: R&D agreement
Compound: new bacterial vaccines employing GlycoVaxyn’s bio-conjugation technology
Company: Glycovaxyn (Switzerland) GSK (UK)
Therapeutic area: Infectious diseases
Type agreement: R&D
development
Action mechanism: GlycoVaxyn\'s bioconjugate vaccine technology uses validated and well understood recombinant DNA techniques along with patented genes to produce \"natural\" carbohydrate-protein conjugates or bioconjugates that can be used as vaccines. GlycoVaxyn\'s bioconjugates can produce functional antibodies that protect against diseases in animal models. In GlycoVaxyn\'s patented process, the gene cluster responsible for the biosynthesis of the bacterial LPS, capsule polysaccharide (CPS) or oligo polysaccharides (oligo PS) is transformed into E. coli together with the protein carrier of interest along with GlycoVaxyn\'s patented enzyme that performs the bioconjugation reaction in vivo. Once produced upon induction, simple purification steps are performed and the biological products are formulated for use as a vaccine. The process of recombinant bioconjugation preserves the bacterial carbohydrate\'s and protein\'s native structure and only produces specific conjugates with a known number of conjugated components. This process yields highly reproducible batches.
Disease:
Details: GlycoVaxyn has announced a collaboration with GlaxoSmithKline Biologicals (GSK) to develop new bacterial vaccines employing GlycoVaxyn’s bio-conjugation technology.The agreement includes an undisclosed set of pathogen targets in the field of bacterial vaccines. GSK retains an option to obtain an exclusive license on these targets during the three-year term of the collaboration and to extend both the term as well as scope of the collaboration.
GlycoVaxyn has developed a portfolio of bio-conjugate vaccines against common severe bacterial infections produced with its proprietary in vivo glycosylation platform. In addition to a clinical stage Shigella vaccine, lead programs in preclinical stage are aimed at the prevention of hospital acquired Staphylococcus aureus infections, as well as pneumococcal invasive diseases and uropathogenic E. coli.
Financial terms: GlycoVaxyn receives an upfront payment and an equity investment. In addition, GlycoVaxyn is eligible to receive milestone payments and royalties on licensed vaccine candidates. Financial terms have not been disclosed.
Latest news:
